Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Hepion presents preclinical study of anti-cancer activity of rencofilstat

Hepion Pharmaceuticals’ (NASDAQ:HEPA) research collaborator presented new findings from a preclinical study on the company’s lead drug candidate, rencofilstat, a potent inhibitor of cyclophilins, at the 2023 State of...

January 11, 2023

Markets

Research Capital starts Eupraxia at speculative buy; PT $10.30 (Canadian)

Research Capital launched coverage of Eupraxia Pharmaceuticals (TSX:EPRX) with a “speculative buy” rating and price target of $10.30 (Canadian). The stock closed at $3.69 on Jan. 6. Eupraxia’s lead product, EP...

January 9, 2023

Developments

Hepion Pharmaceuticals receives non-dilutive funding

Hepion Pharmaceuticals (NASDAQ:HEPA) received $2.9-million in net proceeds from the sale of tax benefits under the company’s participation in the New Jersey Economic Development Authority (NJEDA) net operating loss...

January 9, 2023

Markets

Dawson James starts Zomedica at buy; PT $6

Dawson James initiated coverage of Zomedica (NYSEA:ZOM) with a “buy” rating and price target of $6. The stock closed at 20 cents on Jan. 5. Analyst Jason Kolbert writes that Zomedica is positioning itself as a leading...

January 6, 2023

Developments

Hepion to present Phase 2a rencofilstat multiomics data at NASH-TAG 2023

Hepion Pharmaceuticals (NASDAQ:HEPA) will present an abstract highlighting its lead drug candidate, rencofilstat, at the NASH-TAG 2023 Conference in Park City, Utah on Jan. 7. The presentation is entitled, “Rencofilstat...

January 6, 2023

Markets

Stifel ups Sight Sciences to buy after survey

Stifel upgraded Sight Sciences (NASDAQ:SGHT) to “buy” from “ hold” and raised its price target to $15 from $10 after a survey of 41 minimally invasive glaucoma surgery (MIGS)-trained ophthalmologists “gives us increased...

January 6, 2023

Developments

iBio receives U.S. patent for AI-engineered epitope discovery engine

iBio (NYSEA:IBIO) received a patent from the U.S. Patent and Trademark Office issued a patent entitled, “Machine Learning Method For Protein Modelling To Design Engineered Peptides,” which covers a machine learning...

January 5, 2023

Markets

Cantor resumes coverage of Nano-X Imaging at OW; PT $21

Cantor Fitzgerald resumed coverage of Nano-X Imaging (NASDAQ:NNOX) with an “overweight” rating and 12-month price target of $21 after attending the company’s ARC Day in Israel. The stock closed at $7.60 on Jan. 4. The...

January 5, 2023

Developments

liberDi receives FDA clearance for digital home dialysis system

liberDi, a portfolio company of The Trendlines Group (OTCQX:TRNLY), received regulatory clearance from the FDA for its Digital Dialysis Clinic, which allows patients to perform dialysis at home or at the workplace, by...

January 4, 2023

Markets

HCW starts Poseida Therapeutics at buy; PT $15

H.C. Wainwright initiated coverage of Poseida Therapeutics (NASDAQ:PSTX) with a “buy” rating and $15 price target. The stock closed at $5.79 on Jan. 2. Poseida is a clinical-stage biopharmaceutical company focused on...

January 4, 2023

Markets

Raymond James ups Quipt Home Medical PT after acquisition

Raymond James raised its price target for Quipt Home Medical (NASDAQ:QIPT; TSXV:QIPT) to $14 from $10, and reiterated its “outperform” rating after the company acquired Great Elm Healthcare for about $80-million. The...

January 4, 2023

Developments

Aravive completes enrolment in Phase 3 ovarian cancer trial

Aravive (NASDAQ:ARAV) achieved full enrollment in a global registrational Phase 3 trial of batiraxcept plus paclitaxel for platinum-resistant ovarian cancer (PROC). The Phase 3 AXLerate-OC trial is evaluating efficacy...

January 4, 2023

Hepion presents preclinical study of anti-cancer activity of rencofilstat

Research Capital starts Eupraxia at speculative buy; PT $10.30 (Canadian)

Hepion Pharmaceuticals receives non-dilutive funding

Dawson James starts Zomedica at buy; PT $6

Hepion to present Phase 2a rencofilstat multiomics data at NASH-TAG 2023

Stifel ups Sight Sciences to buy after survey

iBio receives U.S. patent for AI-engineered epitope discovery engine

Cantor resumes coverage of Nano-X Imaging at OW; PT $21

liberDi receives FDA clearance for digital home dialysis system

HCW starts Poseida Therapeutics at buy; PT $15

Raymond James ups Quipt Home Medical PT after acquisition

Aravive completes enrolment in Phase 3 ovarian cancer trial

General

More